Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. - Wikidata - awgldk - TriplyDB

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

http://www.wikidata.org/entity/Q34693066

about

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies Innovation in metabolomics to improve personalized healthcare Metabolomic profiling of hormone-dependent cancers: a bird's eye view Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer (1)H MR spectroscopic imaging of the prostate at 7T using spectral-spatial pulses.Chromatin states reveal functional associations for globally defined transcription start sites in four human cell lines.Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway.Metabolic characterization of triple negative breast cancer.A quantitative analysis of the polyamine in lung cancer patient fingernails by LC-ESI-MS/MS.Discrimination of Basal Cell Carcinoma from Normal Skin Tissue Using High-Resolution Magic Angle Spinning 1H NMR Spectroscopy A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification.Impact of Freezing Delay Time on Tissue Samples for Metabolomic Studies.Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer Prostate MRSI predicts outcome in radical prostatectomy patients.Identification of salivary metabolomic biomarkers for oral cancer screening Biomarkers for prostate cancer: present challenges and future opportunities.Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.A novel non-canonical Wnt signature for prostate cancer aggressiveness.The application of monoclonal antibodies in cancer diagnosis.Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.Systems Biology to Support Nanomaterial Grouping.Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.Tissue Microstructure Is Linked to MRI Parameters and Metabolite Levels in Prostate Cancer.Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.SFRP4 gene expression is increased in aggressive prostate cancer.Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.A Landscape of Metabolic Variation across Tumor Types.Human Suction Blister Fluid Composition Determined Using High-Resolution Metabolomics.Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma Zinc as an Imaging Biomarker of Prostate Cancer

P2860

Q26738585-1F2D7107-AA37-45CE-BD42-89376C7CABCD Q26830021-C3EC6DF9-1FC7-42BE-8C89-CC70DD5428C9 Q28084834-98E99762-4724-423C-A87E-EC46EC5B0C6D Q28828349-DAC3832F-66B6-4679-80E1-463D3396D418 Q28828395-FB8C5330-F4E7-4DCE-8A2A-44EF88A16F1F Q30944933-69F224F3-A806-48F7-8903-A991B3B9E1A5 Q31154613-5FC35486-1C10-46AC-8A5A-812DE271BAC0 Q33866783-83A34F64-5E14-4414-BD37-0D97BD9ECB21 Q34967995-7F56DC22-3B49-46E2-80C2-51154AC8EEBA Q35016571-50DE60BF-0493-4149-9252-3C2C1E2853B0 Q35943239-E4F4D0A0-00C3-4967-B5C2-6C7EA6B43BC8 Q35996026-821F25B9-6E28-46D8-BFE9-5B690363F790 Q36123823-3E0BCBA1-1E1C-47C0-B166-03E03DF505D3 Q36188540-4AA5FA93-523B-4DAC-AC9C-1E5C565A76EA Q36514020-2165F371-C9D1-48C8-8AFB-1644B8A5FE47 Q36738856-889F15CB-52BB-4002-A832-219A9F6FEC8C Q36879999-A703ECA9-8C39-477A-A727-4C38AC23D8B9 Q37188967-6E1B47DC-EA8E-48C4-9D1D-D42BED52EB20 Q37474443-4AC8BCB1-C394-4737-8660-5677FEDC8595 Q37520447-FFA56494-E6AE-4BE7-BAAB-FCE7A3566F9D Q37706021-49FF3DE7-452D-4926-88E2-168E416E4C53 Q38168870-C16A8858-76B0-4DC8-A6C7-CB61844FD365 Q38838580-54A46977-2151-46CE-B3E0-534ED36996E5 Q38974885-B73084B7-3C07-4E70-90A9-DC16DAA49078 Q41957391-AF6D4320-AFCF-4A34-BF31-3937DD6A3C29 Q42726465-AD2D9298-9371-47D4-815F-A66C5CDA1235 Q43104456-7A6C2B49-76BC-4A90-AAEF-9905CDDFD6FD Q45723424-C7791270-C703-40CC-BE66-58BE1CC3CFA7 Q47103101-99C2E8D4-8EFB-4FB6-AF2B-9891321CA2A7 Q49359410-F2BC2A0C-5B17-4547-B008-DF5125CF29A9 Q50100305-5C105BF4-C456-4051-B8C8-01F9833D6EC3 Q50260314-7884F6D8-3720-448A-AD7A-E1908ABF00E2 Q51731326-1B04819E-2C8F-46F0-BA1F-025D53063D3A Q57094654-DD4186A8-0D11-49B9-B431-2301C3C8872B Q57498737-344B65ED-5A18-42F9-811E-B25EFB079C60

P2860

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

http://www.wikidata.org/entity/Q34693066

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@ast

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@en

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@nl

type

label

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@ast

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@en

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@nl

prefLabel

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@ast

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@en

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@nl

P1433

Q34693066-5AFE8C66-FAC1-4E1F-A784-236C32A9C353

P1476

Q34693066-A4D95E8A-8049-4995-9BF9-6FA86C6A197C

P2093

Q34693066-05C904D0-AD30-48E4-B2E4-5F50CCE5B2B5

Q34693066-106E6F32-8A0F-4F22-9C67-08A904147B0F

Q34693066-46791FAA-5B5E-4301-8D5E-E4BEFA169FA1

Q34693066-906F53AF-B5E4-4757-B22B-22D7E5980CDC

Q34693066-A245FCD8-2EB3-439D-AA13-52E4AF387F6D

Q34693066-E4D9BD05-B741-4EED-BA8C-BE8FC1D4BFAD

P2860

Q34693066-04F482FE-1687-49B2-91F7-9C13E9E05642

Q34693066-0526F79D-157A-48DE-8DA5-6F216D39A18E

Q34693066-0576A52E-EA4C-4561-A91D-353EE501050C

Q34693066-0E2FBD3D-98BF-489E-82A8-08D7FD53D975

Q34693066-107E8B44-CBE3-4ED5-829E-1C267043B43B

Q34693066-2DC869FC-C26D-4106-8A13-ACFA08415516

Q34693066-321BBA16-5E82-4A32-8428-3E8E9648605F

Q34693066-36F39516-C2CD-4FF2-90E5-AA80D5BC5488

Q34693066-3AD19CA1-77C6-423E-AA65-801A45EED965

Q34693066-4026AA6C-4302-4ED6-83D5-6F1D623CFF8F

P304

Q34693066-13E5831B-E523-4004-970D-F7E8B2DBE12A

P31

Q34693066-0DF4F859-8858-4768-A104-642F276276BA

P356

Q34693066-90C991FC-A698-434D-9C8E-EC3A932047E9

P407

Q34693066-D6EED209-06A4-47F3-A949-FB7DD362B2B3

P433

Q34693066-2A24876F-2038-468A-8E4A-965B9433FB3F

P478

Q34693066-2A378EC7-41F5-400A-99DE-D64F7899EAFB

P50

Q34693066-20492D64-DD7D-4C29-97F1-1079D201A89D

Q34693066-3661CB2C-D601-4A37-A5C6-1D9AAF526A8F

Q34693066-6738A3F2-CA5A-4BD2-A73F-FB32886D2DDE

Q34693066-BDDADF24-F2CA-4F5E-9805-3CFEB92EF331

P577

Q34693066-18031099-9A28-4E36-947C-E9A259E34025

P5875

Q34693066-77E882F1-8258-484A-B343-FBF248A2D21C

P698

Q34693066-DD5F63CC-CDB3-4B0B-97A9-71C8733768D1

P921

Q34693066-DAF2A96D-3576-4DAF-B71E-66F485E56C4D

P932

Q34693066-7C256D33-B6DD-4FD3-B0F8-728278D36056

P356

JOURNAL.PONE.0062375

P1433

P1476

Spermine and citrate as metabo ...... rostate cancer aggressiveness.

@en

P2093

Alan J Wright

http://www.w3.org/2001/XMLSchema#string

Anders Angelsen

http://www.w3.org/2001/XMLSchema#string

Guro F Giskeødegård

http://www.w3.org/2001/XMLSchema#string

Helena Bertilsson

http://www.w3.org/2001/XMLSchema#string

Kirsten M Selnæs

http://www.w3.org/2001/XMLSchema#string

Trond Viset

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue.

Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.

Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility.

Detection of fully refocused polyamine spins in prostate cancer at 7 T.

Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy.

Prostate MRI and 3D MR spectroscopy: how we do it

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.

Multiparametric magnetic resonance imaging in prostate cancer: present and future

P304

e62375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0062375

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jostein Halgunset

May-Britt Tessem

Ingrid Susann Gribbestad

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236461570

http://www.w3.org/2001/XMLSchema#string

P698

23626811

http://www.w3.org/2001/XMLSchema#string

P921

P932

3633894

http://www.w3.org/2001/XMLSchema#string